{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:18:35Z","timestamp":1764994715534,"version":"3.46.0"},"reference-count":59,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,1,11]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The incidence of cutaneous melanoma (hereafter melanoma) has increased dramatically among fair-skinned populations worldwide. In Norway, melanoma is the most rapidly growing type of cancer, with a 47% increase among women and 57% among men in 2000\u20132016. Intermittent ultraviolet exposure early in life and phenotypic characteristics like a fair complexion, freckles and nevi are established risk factors, yet the aetiology of melanoma is multifactorial. Certain prescription drugs may have carcinogenic side effects on the risk of melanoma. Some cardiovascular, antidepressant and immunosuppressive drugs can influence certain biological processes that modulate photosensitivity and immunoregulation. We aim to study whether these drugs are related to melanoma risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A population-based matched case\u2013control study will be conducted using nation-wide registry data. Cases will consist of all first primary, histologically verified melanoma cases diagnosed between 2007 and 2015 identified in the Cancer Registry of Norway (14 000 cases). Ten melanoma-free controls per case (on date of case melanoma diagnosis) will be matched based on sex and year of birth from the National Registry of Norway. For the period 2004\u20142015, and by using the unique personal identification numbers assigned to all Norwegian citizens, the case\u2013control data set will be linked to the Norwegian Prescription Database for information on drugs dispensed prior to the melanoma diagnosis, and to the Medical Birth Registry of Norway for data regarding the number of child births. Conditional logistic regression will be used to estimate associations between drug use and melanoma risk, taking potential confounding factors into account.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The project is approved by the Regional Committee for Medical Research Ethics in Norway and by the Norwegian Data Protection Authority. The study is funded by the Southeastern Norway Regional Health Authority. Results will be published in peer-reviewed journals and disseminated further through scientific conferences, news media and relevant patient interest groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025246","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T14:07:02Z","timestamp":1550671622000},"page":"e025246","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case\u2013control study"],"prefix":"10.1136","volume":"9","author":[{"given":"Leon Alexander Mclaren","family":"Berge","sequence":"first","affiliation":[{"name":"Department of Research, Kreftregisteret, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina Kulle","family":"Andreassen","sequence":"additional","affiliation":[{"name":"Department of Research, Kreftregisteret, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-5410","authenticated-orcid":false,"given":"Jo Steinson","family":"Stenehjem","sequence":"additional","affiliation":[{"name":"Department of Research, Kreftregisteret, Oslo, Norway"},{"name":"Department of Biostatistics, Universitetet i Oslo Institutt for medisinske basalfag, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger Kristin","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Research, Kreftregisteret, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Nasjonalt folkehelseinstitutt, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asta","family":"Juzeniene","sequence":"additional","affiliation":[{"name":"Department of Radiation Biology, Oslo Universitetssykehus Institutt for kreftforskning, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Roscher","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Dermatology and Infectious Diseases, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond","family":"Heir","sequence":"additional","affiliation":[{"name":"Section for Trauma, Catastrophes and Forced Migration - Adults and Elderly, Nasjonalt kunnskapssenter om vold og traumatisk stress AS, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Green","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit Bragelien","family":"Veier\u00f8d","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Universitetet i Oslo Institutt for medisinske basalfag, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trude Eid","family":"Robsahm","sequence":"additional","affiliation":[{"name":"Department of Research, Kreftregisteret, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2025120519091555000_9.2.e025246.1","unstructured":"The Cancer Registry of Norway. Cancer in Norway 2017. 2018. https:\/\/www.kreftregisteret.no\/en\/General\/Publications\/Cancer-in-Norway\/cancer-in-norway-2017\/ (cited 26 Nov 2018)."},{"key":"2025120519091555000_9.2.e025246.2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.15510","article-title":"The global burden of melanoma: results from the Global Burden of Disease Study 2015","volume":"177","author":"Karimkhani","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025120519091555000_9.2.e025246.3","first-page":"1","article-title":"IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation","volume":"55","author":"Anon","year":"1992","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"2025120519091555000_9.2.e025246.4","unstructured":"IARC. IARC Working group on the evaluation of carcinogenic risk to humans radiation. Lyon (FR): International Agency for Research on Cancer, 2012."},{"key":"2025120519091555000_9.2.e025246.5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/ijc.31527","article-title":"Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012","volume":"143","author":"Arnold","year":"2018","journal-title":"Int J Cancer"},{"key":"2025120519091555000_9.2.e025246.6","doi-asserted-by":"crossref","unstructured":"Berwick M , Buller DB , Cust A . Melanoma Epidemiology and Prevention. In: Kaufman HL , Mehnert JM , eds. Melanoma. Cham: Springer International Publishing, 2016:17\u201349.","DOI":"10.1007\/978-3-319-22539-5_2"},{"key":"2025120519091555000_9.2.e025246.7","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-210","article-title":"New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway","volume":"14","author":"Robsahm","year":"2014","journal-title":"BMC Cancer"},{"key":"2025120519091555000_9.2.e025246.8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12041.x"},{"key":"2025120519091555000_9.2.e025246.9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ijc.31086","article-title":"Anthropometric factors and cutaneous melanoma: Prospective data from the population-based Janus Cohort","volume":"142","author":"Stenehjem","year":"2018","journal-title":"Int J Cancer"},{"key":"2025120519091555000_9.2.e025246.10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00432-017-2387-5","article-title":"Role of BMI and hormone therapy in melanoma risk: a case-control study","volume":"143","author":"De Giorgi","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025120519091555000_9.2.e025246.11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12856"},{"key":"2025120519091555000_9.2.e025246.12","unstructured":"IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Agents classified by the IARC monographs, volumes 123. 2018. https:\/\/monographs.iarc.fr\/agents-classified-by-the-iarc\/ (cited 2018 20 November)."},{"key":"2025120519091555000_9.2.e025246.13","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12946"},{"key":"2025120519091555000_9.2.e025246.14","first-page":"1860","article-title":"[Drugs and sun]","volume":"123","author":"Selv\u00e5g","year":"2003","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025120519091555000_9.2.e025246.15","unstructured":"R\u00f8nning M , Berg C , Furu K , et al . The Norwegian Prescription Database 2005\u20132009: Norwegian Institute of Public Health, 2010."},{"key":"2025120519091555000_9.2.e025246.16","unstructured":"Berg C , Blix HS , Fenne O , et al . The Norwegian Prescription Database 2011\u20132015 (Legemiddelstatistikk 2016:2): Norwegian Institute of Public Health, 2016."},{"key":"2025120519091555000_9.2.e025246.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","article-title":"Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis","volume":"122","author":"Gandini","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025120519091555000_9.2.e025246.18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/OTT.S38403","article-title":"\u03b2-blockers: a novel class of antitumor agents","volume":"5","author":"Ji","year":"2012","journal-title":"Onco Targets Ther"},{"key":"2025120519091555000_9.2.e025246.19","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.131"},{"key":"2025120519091555000_9.2.e025246.20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of \u03b2-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2025120519091555000_9.2.e025246.21","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0249"},{"key":"2025120519091555000_9.2.e025246.22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40264-017-0599-x","article-title":"Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies","volume":"41","author":"Tang","year":"2018","journal-title":"Drug Saf"},{"key":"2025120519091555000_9.2.e025246.23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.clindermatol.2016.05.006","article-title":"Drug-induced photosensitivity: photoallergic and phototoxic reactions","volume":"34","author":"Monteiro","year":"2016","journal-title":"Clin Dermatol"},{"key":"2025120519091555000_9.2.e025246.24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A\u00a0nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025120519091555000_9.2.e025246.25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604686"},{"key":"2025120519091555000_9.2.e025246.26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40264-016-0487-9","article-title":"Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study","volume":"40","author":"Nardone","year":"2017","journal-title":"Drug Saf"},{"key":"2025120519091555000_9.2.e025246.27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamainternmed.2018.1652","article-title":"Association of hydrochlorothiazide use and risk of malignant melanoma","volume":"178","author":"Potteg\u00e5rd","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025120519091555000_9.2.e025246.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.09.004"},{"key":"2025120519091555000_9.2.e025246.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165371","article-title":"Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration","volume":"11","author":"Alvarenga","year":"2016","journal-title":"PLoS One"},{"key":"2025120519091555000_9.2.e025246.30","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-011-9881-x"},{"issue":"Suppl. 61","key":"2025120519091555000_9.2.e025246.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2012.11081.x","article-title":"Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study","volume":"167","author":"de Vries","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025120519091555000_9.2.e025246.32","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00545-5"},{"key":"2025120519091555000_9.2.e025246.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2008.00481.x"},{"key":"2025120519091555000_9.2.e025246.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4072"},{"key":"2025120519091555000_9.2.e025246.35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1600-0625.2012.01531.x","article-title":"Up-regulation of melanin synthesis by the antidepressant fluoxetine","volume":"21","author":"Liao","year":"2012","journal-title":"Exp Dermatol"},{"key":"2025120519091555000_9.2.e025246.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-598","article-title":"Fluoxetine modulates breast cancer metastasis to the brain in a murine model","volume":"14","author":"Shapovalov","year":"2014","journal-title":"BMC Cancer"},{"key":"2025120519091555000_9.2.e025246.37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1734-1140(13)71045-4","article-title":"Inhibitory effect of antidepressants on B16F10 melanoma tumor growth","volume":"65","author":"Grygier","year":"2013","journal-title":"Pharmacol Rep"},{"key":"2025120519091555000_9.2.e025246.38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cbf.1682","article-title":"Antioxidant activity of fluoxetine: studies in mice melanoma model","volume":"28","author":"Kirkova","year":"2010","journal-title":"Cell Biochem Funct"},{"key":"2025120519091555000_9.2.e025246.39","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32834b1894"},{"key":"2025120519091555000_9.2.e025246.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(09)70174-4"},{"key":"2025120519091555000_9.2.e025246.41","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025120519091555000_9.2.e025246.42","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/jamadermatol.2017.2984","article-title":"Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study","volume":"153","author":"Rizvi","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025120519091555000_9.2.e025246.43","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2148"},{"key":"2025120519091555000_9.2.e025246.44","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports (RADAR) project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025120519091555000_9.2.e025246.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.03.019"},{"key":"2025120519091555000_9.2.e025246.46","first-page":"1695","article-title":"Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma","volume":"41","author":"Bhakoo","year":"1981","journal-title":"Cancer Res"},{"key":"2025120519091555000_9.2.e025246.47","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114233"},{"key":"2025120519091555000_9.2.e025246.48","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/jid.2015.312","article-title":"Melanoma Risk and Survival among Organ Transplant Recipients","volume":"135","author":"Robbins","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2025120519091555000_9.2.e025246.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.037"},{"key":"2025120519091555000_9.2.e025246.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"2025120519091555000_9.2.e025246.51","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2015: Norwegian Institute of Public Health, 2016."},{"key":"2025120519091555000_9.2.e025246.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014829","article-title":"A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival","volume":"7","author":"Stenehjem","year":"2017","journal-title":"BMJ Open"},{"key":"2025120519091555000_9.2.e025246.53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2025120519091555000_9.2.e025246.54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Potteg\u00e5rd","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120519091555000_9.2.e025246.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.7078"},{"key":"2025120519091555000_9.2.e025246.56","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025120519091555000_9.2.e025246.57","unstructured":"Core Team R . R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2017."},{"key":"2025120519091555000_9.2.e025246.58","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1677-y"},{"key":"2025120519091555000_9.2.e025246.59","doi-asserted-by":"publisher","DOI":"10.1038\/nature09515"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:09:29Z","timestamp":1764990569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,20]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bmjopen-2018-025246"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025246","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}